uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $56.83

Shares of uniQure N.V. (NASDAQ:QURE – Get Free Report) have received an average rating of “Moderate Buy” from the sixteen research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $55.58.

Several research firms have recently weighed in on QURE. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a report on Wednesday, July 29th. HC Wainwright reduced their target price on uniQure from $80.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday. Barclays cut uniQure from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $60.00 to $28.00 in a research report on Monday, October 5th. Finally, Weiss Ratings upgraded uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st.

View Our Latest Report on uniQure

uniQure Trading Down 0.3%

Shares of QURE opened at $20.23 on Friday. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $51.72. The company’s fifty day moving average is $27.55 and its two-hundred day moving average is $29.62. The company has a current ratio of 11.52, a quick ratio of 11.52 and a debt-to-equity ratio of 0.17.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. uniQure had a negative net margin of 1,154.84% and a negative return on equity of 96.34%. The firm had revenue of $5.20 million during the quarter, compared to the consensus estimate of $6.17 million. Equities analysts predict that uniQure will post -3.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new position in uniQure in the second quarter worth about $15,254. IFP Advisors Inc raised its position in shares of uniQure by 39.8% during the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 791 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in uniQure during the 3rd quarter valued at approximately $86,000. Fulton Bank N.A. bought a new stake in shares of uniQure in the second quarter worth about $220,000. Finally, Activest Wealth Management purchased a new stake in uniQure during the third quarter valued at approximately $121,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.

See Also

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.